How to define follicular thyroid carcinoma?

Virchows Archiv

Volumn 448, Issue 4, 2006, Pages 385-393

  Schmid, Kurt Werner ^a   Farid, Nadir Rashad ^b  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b Osancor Biotech Inc   (United Kingdom)

Author keywords

Follicular adenoma; Follicular thyroid carcinoma; Microarray; Papillary thyroid carcinoma; Poorly differentiated thyroid carcinoma

Indexed keywords

ADENOMA; CANCER INVASION; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENETICS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MICROARRAY ANALYSIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REVIEW; THYROID CARCINOMA; THYROID NODULE; TUMOR DIFFERENTIATION; UPREGULATION;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN ARRAY ANALYSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645567253     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0162-0     Document Type: Review

References (93)

1. Albores-Saavedra J, Gould E, Vardaman C, Vuitch F (1991) The macrofollicular variant of papillary thyroid carcinoma: a study of 17 cases. Hum Pathol 22:1195-1205
2. Albores-Saavedra J, Carrick K (2004) Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid. Endocr Pathol 15:297-305
3. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C (2003) Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63:2864-2871
4. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531-3539
5. Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP (2000) Retinoblastoma expression in thyroid neoplasms. Mod Pathol 13:562-569
6. Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL (1995) Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 4:113-121
7. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey TJ 3rd (2003) Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792-1800
8. Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, Birnbaum D, Malthiery Y, Reynier P, Houlgatte R (2004) Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 89:994-1005
9. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y (2005) Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24:4155-4461
10. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650
11. Berho M, Suster S (1997) The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases. Hum Pathol 28:47-53
12. Bronner MP, LiVolsi VA (1988) Oxyphilic (Askanazy/Hürthle cell) tumors of the thyroid: microscopic features predict biological behaviour. Surg Pathol 1:137-150
13. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain P, Romeo G, Bonneau D (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63:1743-1748
14. Carcangiu ML, Zampi G, Rosai J (1984) Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am J Surg Pathol 8:655-668
15. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J (1991) Follicular Hurthle cell tumors of the thyroid gland. Cancer 68:1944-1953
16. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ (2004) A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242
17. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338-342
18. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL, El-Naggar AK (2004) Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586-6597
19. Chung DH, Kang GH, Kim WH, Ro JY (1999) Clonal analysis of a solitary follicular nodule of the thyroid with the polymerase chain reaction method. Mod Pathol 12:265-271
20. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH (2004) Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123-1129
21. Evans HL, Vassilopoulou-Sellin R (1998) Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22:1512-1520
22. Finley DJ, Zhu B, Barden CB, Fahey TJ III (2004) Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425-437
23. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996
24. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G (2003) ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235
25. Harach HR, Lesueur F, Amati P, Brown A, Canzian F, Kraimps JL, Levillain P, Menet E, Romeo G, Bonneau D (1999) Histology of familial thyroid tumours linked to a gene mapping to chromosome 19p13.2. J Pathol 189:387-393
26. Harrer P, Broecker M, Zint A, Schatz H, Zumtobel V, Derwahl M (1998) Thyroid nodules in recurrent multinodular goiters are predominantly polyclonal. J Endocrinol Invest 21:380-385
27. Hedinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumours. International histological classification of tumours. Springer, Berlin Heidelberg New York
28. Hofstädter F (1980) Frequency and morphology of malignant tumours of the thyroid before and after the introduction of iodine-prophylaxis. Virchows Arch A Pathol Anat Histol 385:263-270
29. Johnson TL, Lloyd RV, Burney RE, Thompson NW (1987) Hurthle cell thyroid tumors. An immunohistochemical study. Cancer 59:107-112
30. Katoh R, Harach HR, Williams ED (1998) Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol 186:292-299
31. Kesmodel SB, Terhune KP, Canter RJ, Mandel SJ, LiVolsi VA, Baloch ZW, Fraker DL (2003) The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 134:1005-1012
32. Kober F, Wolf G, Depisch D, Galvan G, Keminger K, Ladurner D, Langsteger W, Ogris E, Pimpl W, Roka R, Schmalzer E, Schmid KW, Tuchmann A (1990) Schilddrüsenkarzinom. In: Steindorfer P (ed) Manual der chirurgischen Krebstherapie. Springer, Berlin Heidelberg New York, pp 35-48
33. Krohn K, Paschke R (2002) Somatic mutations in thyroid nodular disease. Mol Genet Metab 75:202-208
34. Lang W, Choritz H, Hundeshagen H (1986) Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 10:246-255
35. LiVolsi VA (1990) Surgical pathology of the thyroid. Major problems in pathology, vol 22. Saunders, Philadelphia
36. LiVolsi VA (2003) Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 98:1997-1998
37. Ljungberg O, Bondeson L, Bondeson AG (1984) Differentiated thyroid carcinoma, intermediate type: a new tumor entity with features of follicular and parafollicular cell carcinoma. Hum Pathol 15:218-228
38. Mai KT, Elmontaser G, Perkin DG, Thomas J, Stinson WA (2005) Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol 13:37-41
39. Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG, Leite V (2004) Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPAR gamma-negative thyroid tumours. Br J Cancer 91:732-738
40. Maximo V, Sores P, Rocha AS, Sobrinho-Simoes M (1998) The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastruc Pathol 22:271-273
41. Maximo V, Sobrinho-Simoes M (2000) Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437:107-115
42. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160:1857-1865
43. Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simoes M (2005) Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92:1892-1898
44. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK (2004) Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903
45. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J (1996) Hurthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 120:1000-1004
46. Mendelsohn G (1988) Pathology of thyroid disease. In: Mendelsohn G (ed) Diagnosis and pathology of endocrine disease. J.B. Lippincott, Philadelphia, pp 37-117
47. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, Kobayashi K, Terada T (2001) Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int 51:680-685
48. Müller-Hocker J, Jacob U, Seibel P (1998) Hashimoto thyroiditis is associated with defects of cytochrome-c oxidase in oxyphil Askanazy cells and with the common deletion (4,977) of mitochondrial DNA. Ultrastruct Pathol 22:91-100
49. Musholt PB, Imkamp F, von Wasielewski R, Schmid KW, Musholt TJ (2003) RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 134:881-889
50. Nesland JM, Sobrinho-Simoes MA, Holm R, Sambade MC, Johannessen JV (1985) Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct Pathol 8:269-290
51. Nibu K-I, Otsuko N, Nakao K, Sugasawa M, Rothstein JL (2005) RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas. Eur Arch Otorhinolaryngol 262:368-373
52. Nikiforov YE (2004) Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol 15:319-327
53. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE (2003) Ras point mutations and PAX8-PPAR gamma rearrangements in thyroid tumours: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326
54. Papotti M, Botto Micca F, Favero A, Palestini N, Bussolati G (1993) Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol 17:291-301
55. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G (1996) Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 20:686-694
56. Pilotti S, Collini P, Mariani L, Placucci M, Bongarzone I, Vigneri P, Cipriani S, Falcetta F, Miceli R, Pierotti MA, Rilke F (1997) Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol 21:1466-1473
57. Puskas LG, Farid NR (2004) Gene expression in thyroid tumors. In: Farid NR (ed) The molecular basis of thyroid cancer. Kluwer, Boston, pp 265-271
58. Puskas LG, Juhasz F, Farid NR (2004) Microarray study of malignant and benign nodular thyroid tissue. In: 86th annual meeting of the Endocrine Society, Abstract P2, New Orleans, p 183
59. Puskas LG, Juhasz F, Zarva A, Hackler L Jr, Farid NR (2005) Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Mol Cell Biol 51:177-186
60. Raphael SJ (2002) The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 13:301-311
61. Rosai J, Carcangiu ML, DeLellis RA (1992) Tumors of the thyroid gland. Atlas of tumor pathology, 3rd series, vol 5. AFIP, Washington, DC
62. Rosai J (2004) Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol 15:293-296
63. Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849-1855
64. Schmid KW, Tötsch M, Hittmair A, Feichtinger H, Ladurner D, Hofstädter F (1989) Frequency of medullary thyroid carcinoma in an endemic area. Mod Pathol 2:90-93
65. Schmid KW, Tötsch M, Öfner D, Böcker W, Ladurner D (1997) Minimally invasive follicular thyroid carcinoma. A clinicopathological study. In: Schmid KW, Böcker W (eds) Thyroid pathology. Current topics in pathology. Springer, Berlin Heidelberg New York, pp 37-44
66. Schmid KW (1998) Does the encapsulated oxyphilic variant of papillary thyroid carcinoma really exist? J Pathol 184:31A
67. Schmid KW, Sheu S-Y, Görges R, Ensinger C, Tötsch M (2003) Tumoren der Schilddrüse. Pathologe 24:357-372
68. Schröder S (1988) Pathologie und Klinik maligner Schilddrüsentumoren. Gustav Fischer Verlag, Stuttgart
69. Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131-1136
70. Shahedian B, Shi Y, Zou M, Farid NR (2001) Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 72:155-163
71. Shi Y, Zou M, Varkondi E, Nagy A, Kozma L, Farid NR (2001) Cyclin D1 in thyroid carcinomas. Thyroid 10:741-746
72. Sneed DC (1999) Protocol for the examination of specimens from patients with malignant tumors of the thyroid gland, exclusive of lymphomas. Arch Pathol Lab Med 123:45-49
73. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580
74. Sobrinho-Simoes MA, Nesland JM, Holm R, Sambade MC, Johannessen JV (1985) Hurthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 8:131-142
75. Sobrinho-Simoes M, Maximo V, Castro FV, Fonseca E, Soares P, Garcia-Rostan G, Oliveira MC (2005) Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol 13:29-35
76. Stewart BW, Kleihues P (2003) World cancer report. IARC Press, Lyon, pp 257-260
77. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N (2004) High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 90:1600-1605
78. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N (2005) Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma. Cancer Lett 219:91-96
79. Tallini G (1998) Oncocytic tumours. Virchows Arch 433:5-12
80. Thomas D, Lizyness M, Kuick R, Sanders D, Misek D, Hanash S, Nikiforov Y, Koenig R, Giorando TJ (2004) Gene expression signature of oncocytic (Hurthle cell) thyroid carcinoma. Thyroid 14:713
81. Thomas GA, Williams D, Williams ED (1989) The clonal origin of thyroid nodules and adenomas. Am J Pathol 134:141-147
82. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595
83. Valenta LJ, Michel-Bechet M, Warshaw JB, Maloof F (1974) Human thyroid tumors composed of mitochondrion-rich cells: electron microscopic and biochemical findings. J Clin Endocrinol Metab 39:719-733
84. Vickery AL Jr, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M (1985) Papillary carcinoma. Semin Diagn Pathol 2:90-100
85. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG (2004) Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950-957
86. Volante M, Cavallo GP, Papotti M (2004) Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid. Endocr Pathol 15:313-317
87. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF (1984) Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 59:851-855
88. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C (2005) Genetic classification of benign and malignant follicular neoplasm based on a 3-gene combination. J Clin Endocrinol Metab 90:2512-2521
89. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) WHO histological classification of thyroid and parathyroid tumours. World Health Organization classification of tumours. Pathology & genetics. Tumours of endocrine organs. IARC Press, Lyon, pp 49-123
90. Williams ED, Doniach I, Bjarnson O, Michie W (1977) Thyroid cancer in an iodine rich area. Cancer 39:215-222
91. Williams ED (2000) Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181-183
92. Wynford-Thomas D (1994) Thyroid cancer. In: Lemoine N, Neoptolemos J, Cooke T (eds) Cancer. A molecular approach. Blackwell Scientific Publications, Oxford, pp 192-222
93. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K (2004) Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10:2035-2043